Radiologists are often called to review scans of patients who have undergone therapeutic treatment for cancer. In such scenarios, accurate assessment of tumor volume is key to knowing whether the therapy is effective.
Radiologists are often called to review scans of patients who have undergone therapeutic treatment for cancer. In such scenarios, accurate assessment of tumor volume is key to knowing whether the therapy is effective.
Dr. Francesco Fraioli and colleagues from the University of Rome La Sapienza evaluated a CAD system's ability to assess tumor volume in nine patients undergoing chemotherapy for lung metastases. They applied RECIST criteria to consider the disease as stable, increased, or decreased and compared CAD findings to observers' measurements.
Researchers included 24 nodules in the study, ranging from 5 mm to 18 mm before therapy and 4 mm to 20 mm post-therapy. Observers agreed in the assessment of therapy response in 21 nodules: eight were considered increased in volume, and 13 were judged stable.
Observers and CAD measurements disagreed in three nodules: two considered as stable by radiologists and increased by CAD; one considered increased by radiologists and stable by CAD.
Fraioli, who presented the study at the 2006 European Congress of Radiology, concluded that CAD volumetric measurements allow an easy and objective evaluation, reducing interobserver variability.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.